ChiCTR2400085172 版本V1.0 版本创建时间2024/05/31 20:15:44 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400085172 

最近更新日期:

Date of Last Refreshed on:

2024-05-31 20:15:32 

注册时间:

Date of Registration:

2024-05-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于眼动试验的认知障碍筛查系统的探索性研究

Public title:

Screening system for people at high risk of cognitive impairment based on eye movement test: An exploratory study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于眼动试验的认知障碍筛查系统的探索性研究

Scientific title:

Screening system for people at high risk of cognitive impairment based on eye movement test: An exploratory study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

司唯 

研究负责人:

司唯;朱爱勇 

Applicant:

Si Wei 

Study leader:

Si Wei; Zhu Aiyong 

申请注册联系人电话:

Applicant telephone:

+86 180 1640 3878

研究负责人电话:

Study leader's telephone:

+86 133 8627 2991

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

stacysiwei@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhuay@sumhs.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区华佗路280弄22-27幢604

研究负责人通讯地址:

上海市浦东新区周祝公路279号6号楼302

Applicant address:

Room 604, Building 22-27, Lane 280, Huatuo Road, Pudong New Area, Shanghai

Study leader's address:

Room 302, Building 6, 279 ZhouZHU Highway, Pudong NEW Area, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

201318

研究负责人邮政编码:

Study leader's postcode:

201318

申请人所在单位:

上海中医药大学研究生院

Applicant's institution:

Graduate School of Shanghai University of Traditional Chinese Medicine

研究负责人所在单位:

上海健康医学院护理与健康管理学院

Affiliation of the Leader:

School of Nursing and Health Management, Shanghai University of Medicine & Health Sciences

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-yjskt-02-321322200003304621

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海健康医学院护理与健康管理学院分学术委员会

Name of the ethic committee:

Sub-academic Committee of School of Nursing and Health Management, Shanghai University of Medicine &Health Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2024-05-15 00:00:00

伦理委员会联系人:

郭颖达

Contact Name of the ethic committee:

Guo Ying-da

伦理委员会联系地址:

上海市浦东新区周祝公路279号6号楼307

Contact Address of the ethic committee:

Shanghai pudong new area Zhou Zhu highway 6, 279, 405

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 133 8627 2991

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zhuay@sumhs.edu.cn

研究实施负责(组长)单位:

上海健康医学院护理与健康管理学院

Primary sponsor:

School of Nursing and Health Management, Shanghai University of Medicine & Health Sciences

研究实施负责(组长)单位地址:

上海市浦东新区周祝公路279号6号楼301

Primary sponsor's address:

Shanghai pudong new area Zhou Zhu highway 6, 279, 301

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海健康医学院

具体地址:

上海市浦东新区周祝公路279号

Institution
hospital:

Shanghai University of Medicine &Health Sciences

Address:

Shanghai pudong new area Zhou Zhu highway, 279

经费或物资来源:

上海市科研计划项目(23010502900); 2023 年老年长期照护教育部重点实验室开放基金重点项目(LNZD-2023-01)

Source(s) of funding:

Shanghai Scientific Research Program, No.23010502900; 2023 Key Laboratory Open Fund Project of Ministry of Education for Elderly and Elderly Care (LNZD-2023-01)

Target disease:

Cognitive Impairment

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

本研究旨在通过分析眼球运动轨迹任务数据,设计开发一款适用于中国老年群体的无感化、交互式认知症早期筛查系统,验证该系统对认知正常和认知症患者的区分效度,评估该系统与常用认知量表的相关性,为护理人员早期筛查认知症提供一种高效可行的工具,加速落实健康老龄化在认知症数字化评估领域的社会面普及。  

Objectives of Study:

The purpose of this study is to design and develop a user-friendly and interactive early screening system for cognitive impairment in the elderly in China by analyzing the data of eye movement tracking tasks, verify the discrimination validity of the system for normal cognitive patients and cognitive impairment patients, evaluate the correlation between the system and common cognitive scales, and provide an efficient and feasible tool for nursing staff to screen for cognitive impairment early. To accelerate the social popularization of healthy aging in the field of digital dementia assessment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄≥60岁的老年人;②患者本人或家属知情同意;③愿意配合完成认知功能检查;④愿意配合研究和提供自身相关资料者。

Inclusion criteria

① Aged ≥60 years old; ② Informed consent of patients or their families; ③ willing to cooperate with the cognitive function examination; ④ Willing to cooperate with the research and provide their own relevant information.

排除标准:

①其他重大躯体疾病、严重影响视力、听力的疾病。②不能理解测试内容并独立配合完成完整测试。

Exclusion criteria:

① Other serious physical diseases, diseases that seriously affect vision and hearing. ② Unable to understand the test content and cooperate to complete the test independently.

研究实施时间:

Study execute time:

From 2023-12-01 00:00:00 To 2025-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-01 00:00:00 To 2024-11-01 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

MCI组:符合Petersen诊断标准的MCI患者,具体如下:①由病患或知情人报告,或由临床医师发现认知损害情况;②存在客观证据证明的认知功能受损(1个或多个认知域);③患者具备自理能力,日常生活不存在障碍,但一些较为复杂的工具性能力会受到轻度损害。④尚未达到痴呆的诊断 AD组:符合NINCDS-ADRDA AD诊断标准:①痴呆:临床检查和认知量表检测确定有痴呆;②两个或以上认知功能缺损且进行性恶化;③无意识障碍;④40-90岁起病,多见于65岁以后;⑥排除其他引起进行性记忆和认知功能损害的系统性疾病和脑部疾病。 受试者经过神经心理医师MMSE及MoCA评分标准化测评。受试者MMSE及MoCA各项评分由专业神经心理师评估并记录。MoCA评分以受教育年限≤12年向上修正1分,大于等于26分为认知正常,19~25分为MCI,≤18分为痴呆。MMSE评分以文化程度校正后的临界值(大学及以上26分,中学24分,小学23分,文盲 22分)分别用于筛查痴呆和MCI,灵敏度和特异度较高,两者组合检查可以提高检出率。在MMSE与MoCA整体认知筛查量表进行认知评定后,将受试者划分为正常认知组和认知障碍组。 对于认知障碍组在此基础上进行认知障碍诊断,神经心理医师利用临床痴呆评定量表CDR、日常生活活动能力量表ADL、神经精神科问卷NPI,依照诊断依据给出MCI或AD诊断

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

MCI group: Patients with MCI who met Petersen's diagnostic criteria as follows: (1) Cognitive impairment reported by patients or insiders, or identified by clinicians; There is objective evidence of impaired cognitive function (one or more cognitive domains); (3) Patients have self-care ability and there are no obstacles in daily life, but some of the more complex instrumental abilities will be slightly damaged. ④ The diagnosis of dementia has not yet been reached AD group: In accordance with NINCDS-ADRDA diagnostic criteria for AD: ① Dementia: clinical examination and cognitive scale detection confirmed dementia; 2 or more cognitive impairment and progressive deterioration; ③ Unconscious disorders; (4) The onset of the disease between 40 and 90 years old is more common after 65 years old; Rule out other systemic diseases and brain diseases that cause progressive memory and cognitive impairment. Participants were assessed by neuropsychologist MMSE and MoCA scores. Subjects' MMSE and MoCA scores were evaluated and recorded by professional neuropsychologists. The MoCA score was revised upward by 1 point with the years of education ≤12 years, greater than or equal to 26 was classified as cognitive normal, 19-25 was classified as MCI, and ≤18 was classified as dementia. The MMSE score was adjusted for cutoff values (university and above 26 points, secondary school 24 points, primary school 23 points, illiterate 22 points) to screen for dementia and MCI, respectively, with high sensitivity and specificity, and the combination of the two tests can improve the detection rate. After the cognitive assessment of MMSE and MoCA global cognitive screening scale, the subjects were divided into normal cognitive group and cognitive impairment group. For the cognitive impairment group, the diagnosis of cognitive impairment was made on this basis. Neuropsychologists used the clinical dementia rating scale CDR, the Activity of daily living Scale ADL, and the neuropsychiatric questionnaire NPI to give the diagnosis of MCI or AD according to the diagnostic basis

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

基于眼动试验的认知障碍早期筛查系统

Index test:

An early screening system for cognitive impairment based on eye movement tests

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

轻度认知功能障碍及认知症患者

例数:

Sample size:

116

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

People with mild cognitive impairment and people with dementia

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

主观认知下降人群

例数:

Sample size:

58

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Ppeople with subjective cognitive decline

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市浦东新区航头社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Shanghai Pudong New Area Hangtou Community Health Service center

Level of the institution:

Community Health Service Center,

测量指标:

Outcomes:

指标中文名:

眼动认知障碍筛查系统得分

指标类型:

主要指标

Outcome:

Eye movement cognitive impairment screening system score

Type:

Primary indicator

测量时间点:

测量方法:

系统评分

Measure time point of outcome:

Measure method:

System scoring

指标中文名:

认知状态评分

指标类型:

主要指标

Outcome:

Cognitive status score

Type:

Primary indicator

测量时间点:

测量方法:

MMSE,MoCA评分

Measure time point of outcome:

Measure method:

MMSE,MoCA scale

指标中文名:

瞳孔注视时间

指标类型:

次要指标

Outcome:

Pupil fixation time

Type:

Secondary indicator

测量时间点:

测量方法:

视觉数据采集设备后台导出

Measure time point of outcome:

Measure method:

Visual data acquisition equipment background export

指标中文名:

受试者工作曲线

指标类型:

主要指标

Outcome:

Receiver Operating Characteristic curve, ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

曲线下面积

指标类型:

主要指标

Outcome:

Area Under the Curve, AUC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

同时效度

指标类型:

主要指标

Outcome:

Concurrent Validity

Type:

Primary indicator

测量时间点:

测量方法:

采用Spearman相关,评估该系统得分与MMSE得分、MoCA得分的同时效度

Measure time point of outcome:

Measure method:

Spearman correlation was used to evaluate the simultaneous validity of the system score, MMSE score and MoCA score

指标中文名:

准确度

指标类型:

主要指标

Outcome:

Accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

灵敏度

指标类型:

次要指标

Outcome:

Sensitivity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

次要指标

Outcome:

Specificity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质量表由研究人员进行采集及保存,并且录入excel表格中,眼动试验筛查系统所采集的眼动数据由后台直接导出至电子采集和管理平台

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The paper scale was collected and saved by researchers and recorded into excel tables. The eye movement data collected by the eye movement test screening system was directly exported from the background to the electronic collection and management platform

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-05-31 20:15:32